Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy.
Pierga JY, Reis-Filho JS, Cleator SJ, Dexter T, Mackay A, Simpson P, Fenwick K, Iravani M, Salter J, Hills M, Jones C, Ashworth A, Smith IE, Powles T, Dowsett M. Pierga JY, et al. Among authors: cleator sj. Br J Cancer. 2007 Jan 29;96(2):341-51. doi: 10.1038/sj.bjc.6603483. Epub 2006 Nov 28. Br J Cancer. 2007. PMID: 17133270 Free PMC article.
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer.
Haynes BP, Schuster G, Buus R, Alataki A, Ginsburg O, Quang LH, Han PT, Khoa PH, Van Dinh N, Van To T, Clemons M, Holcombe C, Osborne C, Evans A, Skene A, Sibbering M, Rogers C, Laws S, Noor L, Cheang MCU, Cleator SJ, Smith IE, Dowsett M. Haynes BP, et al. Among authors: cleator sj. Breast Cancer Res Treat. 2021 Nov;190(2):295-305. doi: 10.1007/s10549-021-06377-3. Epub 2021 Sep 15. Breast Cancer Res Treat. 2021. PMID: 34524591 Free PMC article.
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Bergamino MA, López-Knowles E, Morani G, Tovey H, Kilburn L, Schuster EF, Alataki A, Hills M, Xiao H, Holcombe C, Skene A, Robertson JF, Smith IE, Bliss JM, Dowsett M, Cheang MCU; POETIC investigators. Bergamino MA, et al. EBioMedicine. 2022 Sep;83:104205. doi: 10.1016/j.ebiom.2022.104205. Epub 2022 Aug 16. EBioMedicine. 2022. PMID: 35985932 Free PMC article.
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. Lin NU, et al. Among authors: cleator s. Breast Cancer Res Treat. 2012 Jun;133(3):1057-65. doi: 10.1007/s10549-012-2003-y. Epub 2012 Mar 15. Breast Cancer Res Treat. 2012. PMID: 22418700 Free PMC article. Clinical Trial.
66 results